Press Release
Feb 01, 2021
Chris Martin CMartin@DavidJamesGroup.com | 630-670-2745
DENVER- The International Association for the Study of Lung Cancer (IASLC) has selected Brisbane, Australia resident Anita McGrath as a participant for the Supportive Training for Advocates on Research and Science (STARS) Program as a Patient Research Advocate (PRA).
The STARS program aims to help patient advocates evolve into patient research advocates—a distinction explained by a PRA’s ability to bring the patient voice to research-related efforts. PRAs work with clinicians and scientists to provide the patient perspective for lung cancer research and policy.
McGrath was diagnosed in January 2014 with stage III non-small cell lung cancer, at the age of 44. She began treatment with chemotherapy and radiation and was then found to have a genomic alteration known as an ALK fusion. She was treated with a tyrosine kinase inhibitor, a therapy that has been shown to successfully treat certain forms of cancer.
As part of her lung cancer journey, she has become a lung cancer advocate to support others with lung cancer and raise awareness that anyone with any medical history and at any stage of life can get lung cancer. She’s also worked with numerous nonprofit organizations and government health departments. Recently, she’s focused on consumer perspective work within the research field. She’s currently a consumer in research with the Thoracic Oncology Group of Australasia (TOGA) and the Australasian Lung Cancer Trials group (ALTG).
STARS Mentors and PRAs will receive complimentary registration to attend the IASLC 2020 World Conference on Lung Cancer (WCLC), to be held virtually January 28-31, 2021. The WCLC is the largest international conference specific to lung cancer. To prepare for WCLC, Mentors and PRAs will participate in communication learning labs through Research Advocacy Network, education sessions and meetings with key opinion leaders in the lung cancer community.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes nearly 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2020.iaslc.org.